Etanercept therapy in Rheumatic diseases

Speciality: Rheumatology


Speaker:

Dr. Anish Aggarwal - Moderator | Rheumatologist

Dr. Kiran Seth - Panelist | Rheumatologist

Dr. Gaurav Seth - Panelist | Rheumatologist

Dr. Gaurav Jain - Panelist | Rheumatologist

Description:

A warm welcome to all the medical professionals in this interesting session on etanercept therapy in rheumatic diseases

Etanercept is a biologic medication used to treat various rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It works by inhibiting tumor necrosis factor (TNF), a protein involved in inflammation. By blocking TNF, Etanercept helps reduce inflammation, pain, and joint damage.

In rheumatoid arthritis, Etanercept has shown to significantly improve symptoms and slow disease progression. Patients experience relief from joint stiffness, swelling, and pain, leading to better physical function. It is often prescribed when other treatments, like methotrexate, do not provide sufficient results.

For psoriatic arthritis and ankylosing spondylitis, Etanercept also offers benefits by reducing joint inflammation and preventing further joint damage. It helps improve mobility and overall quality of life. However, long-term use requires regular monitoring, as it can increase the risk of infections and other side effects.

Overall, Etanercept provides an effective treatment option for patients with rheumatic diseases, especially when conventional therapies fall short.

Therefore, get an overall knowledge of etanercept therapy in rheumatic diseases. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

3.

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot